Alexion

web_corporate-logo-rgb

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies – Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D). Alexion also developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas. www.alexion.com